Friendly Competition Fosters Progress in Hematologic Malignancies: "These are price/ess accomplishments that impact the lives of people.".

Citation metadata

Author: Elias Jabbour
Date: June 2021
From: Oncology(Vol. 35, Issue 6)
Publisher: Intellisphere, LLC
Document Type: Interview
Length: 1,269 words
Lexile Measure: 1160L

Document controls

Main content

Article Preview :

Treatment selection for patients with hematologic malignancies involves a vast knowledge of variations in biology and the rapidly evolving field of systemic therapy development. With options for transplant, chimeric antigen receptor (CAR) T-cell therapy, tyrosine kinase inhibitors (TKIs), and immunotherapy in most tumor types, appropriate therapy selection for a given patient is far from straightforward or standard.

To discuss this and emerging breakthroughs, Elias Jabbour, MD, a professor of medicine in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, reflected on his body of work and how competition among colleagues motivated his contributions to the field of medicine.

"I had an opportunity to work with giants in cancer. These are people who are heroes in treating cancer," Jabbour said. "Working with them, you have to be at a level [where you] work hard and you have great competition to do the best you can."

Continuing with the theme of friendly competition, Jabbour discussed the 5th Annual Live Medical Crossfire[R]: Hematologic Malignancies, hosted by Physicians' Education Resource, LLC (PER[R]), to be held Saturday, July 17, 2021, for which he is the cochair. The annual event considers emerging topics by presenting contrasting viewpoints of key opinion leaders across a broad range of hematologic malignancies. By exploring the issues from different perspectives, clinicians may be better equipped to treat a wide range of patients.

"With leukemias and hematology [in general], these are rare diseases compared with solid tumors. People who treat hematologic malignancies have a major interest in the field," he said. "Leukemia, in particular, is really evolving at a very high speed. Every year, we see new therapies [and] a new standard of care. It's hard to keep pace with the evolution... these are priceless accomplishments that impact the lives of people."

In preparation for the meeting, Jabbour sat down with ONCOLOGY[R] to discuss emerging trends in leukemias,...

Source Citation

Source Citation   

Gale Document Number: GALE|A677572498